Discontinuation of Dialysis After ¹⁷⁷Lu-PSMA Therapy in mCRPC With Malignant Obstructive Uropathy

Clinical Nuclear Medicine 2026

View at publisher
Authors: Enes Yerdeş, Ebuzer Kalender
DOI: 10.1097/rlu.0000000000006441
Cited by: 1
References: 6

Abstract

A major complication of advanced prostate cancer is malignant obstructive uropathy, a condition that can precipitate post-renal acute kidney injury and ultimately require hemodialysis intervention. We present a striking imaging example of a patient with metastatic castration-resistant prostate cancer (mCRPC) and dialysis-dependent renal failure who demonstrated marked tumor regression and discontinuation of dialysis following 177 Lu-PSMA radioligand therapy.

Fields of Study & Subjects

Prostate Cancer Treatment and Research Prostate Cancer Diagnosis and Treatment Radiopharmaceutical Chemistry and Applications

Publication details

Journal / source
Clinical Nuclear Medicine
Publisher
Ovid Technologies (Wolters Kluwer Health)
Volume
51
Issue
9
Pages
e840–e841
Publication date
24 March 2026
Language
EN